| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payment of deferred financing costs | - | 178 |
| Net cash provided by financing activities | 237,061 | 18,907 |
| Net increase (decrease) in cash and cash equivalents | 158,734 | -11,431 |
| Cash and cash equivalents at beginning of period | 87,928 | - |
| Cash and cash equivalents at end of period | 246,662 | - |
SOLENO THERAPEUTICS INC (SLNO)
SOLENO THERAPEUTICS INC (SLNO)